Covered recipient · General Payments record
MATTHEW L SMITH
Allopathic & Osteopathic Physicians Obstetrics & Gynecology
General Payments · PY2018–2024
$3,442.82
- Reported across 182 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $401.29 | 15 |
| Education | $94.00 | 1 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Astellas Pharma US Inc | $179.52 | 5 |
| Organon LLC | $125.97 | 1 |
| Exeltis, USA Inc. | $62.66 | 4 |
| PFIZER INC. | $41.89 | 2 |
| Sumitomo Pharma America, Inc. | $24.45 | 1 |
| Sage Therapeutics, Inc. | $23.50 | 1 |
| Daiichi Sankyo Inc. | $23.19 | 1 |
| SHIELD THERAPEUTICS INC | $14.11 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (16)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Astellas Pharma US Inc | $16.97 | 03/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139272834 | CMS |
| Astellas Pharma US Inc | $94.00 | 03/18/2024 | Education | Undisputed | 01/23/2026 | 1139344918 | CMS |
| Astellas Pharma US Inc | $18.81 | 05/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139352761 | CMS |
| Astellas Pharma US Inc | $26.29 | 05/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139358931 | CMS |
| Astellas Pharma US Inc | $23.45 | 11/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139435418 | CMS |
| Daiichi Sankyo Inc. | $23.19 | 03/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1089484646 | CMS |
| Exeltis, USA Inc. | $15.37 | 01/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1150004974 | CMS |
| Exeltis, USA Inc. | $15.53 | 02/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1150004976 | CMS |
| Exeltis, USA Inc. | $13.79 | 05/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1150004978 | CMS |
| Exeltis, USA Inc. | $17.97 | 06/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1150004980 | CMS |
| Organon Llc | $125.97 | 09/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1136236030 | CMS |
| PFIZER INC. | $18.62 | 05/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131641367 | CMS |
| PFIZER INC. | $23.27 | 07/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131748308 | CMS |
| Sage Therapeutics, Inc. | $23.50 | 03/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1120406501 | CMS |
| SHIELD THERAPEUTICS INC | $14.11 | 12/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1150156010 | CMS |
| Sumitomo Pharma America, Inc. | $24.45 | 03/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1148921689 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.